Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (421-430 of 744) with videos related to

Pageof 75
Sort By:
Oncotarget|October 6, 2016
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomasMałgorzata Czyż, Monika Toma, Anna Gajos-Michniewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsRoger von Moos, Beat J K Thuerlimann, Matti Aapro, et al.
Oncotarget|December 2, 2016
Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migrationVida Farsam, Abhijit Basu, Martina Gatzka, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Cancers|March 13, 2024
Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in SwitzerlandRamon Staeger, Julia M Martínez-Gómez, Patrick Turko, et al.
The Journal of Investigative Dermatology|May 12, 2020
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionMai Q Nguyen, Jessica L F Teh, Timothy J Purwin, et al.
Immunity|April 19, 2015
Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical responseLaura Surace, Veronika Lysenko, Andrea Orlando Fontana, et al.
Pigment Cell Research|July 11, 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signatureKeith S Hoek, Natalie C Schlegel, Patricia Brafford, et al.
Molecular Cancer Therapeutics|June 28, 2015
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2Sandra N Freiberger, Phil F Cheng, Guergana Iotzova-Weiss, et al.
Oncotarget|December 6, 2019
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2<sup>S310F</sup> mutated extramammary Paget's diseaseThierry M Nordmann, Olivia Messerli-Odermatt, Larissa Meier, et al.
Pageof 75

Showing results (421-430 of 744) with videos related to

Sort By:
Pageof 75
Oncotarget|October 6, 2016
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomasMałgorzata Czyż, Monika Toma, Anna Gajos-Michniewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsRoger von Moos, Beat J K Thuerlimann, Matti Aapro, et al.
Oncotarget|December 2, 2016
Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migrationVida Farsam, Abhijit Basu, Martina Gatzka, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Cancers|March 13, 2024
Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in SwitzerlandRamon Staeger, Julia M Martínez-Gómez, Patrick Turko, et al.
The Journal of Investigative Dermatology|May 12, 2020
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionMai Q Nguyen, Jessica L F Teh, Timothy J Purwin, et al.
Immunity|April 19, 2015
Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical responseLaura Surace, Veronika Lysenko, Andrea Orlando Fontana, et al.
Pigment Cell Research|July 11, 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signatureKeith S Hoek, Natalie C Schlegel, Patricia Brafford, et al.
Molecular Cancer Therapeutics|June 28, 2015
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2Sandra N Freiberger, Phil F Cheng, Guergana Iotzova-Weiss, et al.
Oncotarget|December 6, 2019
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2<sup>S310F</sup> mutated extramammary Paget's diseaseThierry M Nordmann, Olivia Messerli-Odermatt, Larissa Meier, et al.
Pageof 75